Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Product-news crawled date : 2021 - 05 - 05 save search
NLS Pharmaceutics Announces Patent Issuance in Europe for its Mazindol Controlled-Release Formulation (Mazindol CR)
Published: 2021-05-05 (Crawled : 14:15) - biospace.com/
NLSP | $0.133 6.04% 96K
|
|
| O: 0.0%
H: 1.19%
C: -3.87%
europe patent
FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis
Published: 2021-05-05 (Crawled : 14:15) - biospace.com/
BGNE | $131.94 0.06% 0.06% 130K
|
Health Technology
|
| O: -0.5%
H: 3.2%
C: -1.07%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.43%
H: 1.5%
C: 1.24%
new drug fda drug psoriasis fda acceptance application plague
Nemaura Medical Announces Order for 200,000 sugarBEAT® Sensors
Published: 2021-05-05 (Crawled : 13:15) - biospace.com/
NMRD | $0.1053 -28.78% 820K
|
Health Technology
|
| O: 3.62%
H: 143.94%
C: 127.1%
sensor order
New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test
Published: 2021-05-05 (Crawled : 13:15) - biospace.com/
CSTL | $19.19 1.86% 1.82% 140K
|
Health Technology
|
| O: 0.65%
H: 1.01%
C: -4.44%
eye test
Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report
Published: 2021-05-05 (Crawled : 13:15) - biospace.com/
TEVA | $12.78 -3.03% -0.24% 9M
|
Health Technology
|
| O: 1.09%
H: 1.96%
C: 1.57%
ev
Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab)
Published: 2021-05-05 (Crawled : 12:15) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.1%
H: 0.59%
C: 0.22%
REPL | $6.98 -3.19% -3.3% 1.1M
|
Health Technology
|
| O: 2.18%
H: 12.36%
C: 6.47%
clinical trials trial
Editas Medicine Announces First Quarter 2021 Results and Update
Published: 2021-05-05 (Crawled : 12:15) - biospace.com/
EDIT | $5.56 -0.89% -0.9% 1.7M
|
Health Technology
|
| O: 0.98%
H: 5.34%
C: -0.8%
results
Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of Drug Candidates EarlierFirst-of-its-kind software predicts likelihood of off-target safety issues that could impede clinical progress
Published: 2021-05-04 (Crawled : 00:00) - biospace.com/
CERT | $16.19 -4.48% -4.69% 490K
|
|
| O: -0.98%
H: 1.43%
C: -4.23%
software risk drug
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.